Phaseline

Targets › ADRA2B

ADRA2B (Alpha-2B adrenergic receptor): drug programs, companies and trials

39 programs from 38 companies in 141 trials: 51 Phase 4, 42 Phase 2, 25 Phase 3, 23 Phase 1; Psychiatry, Other, Ophthalmology; next expected readout Nov 2026.

Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. (UniProt, P18089)

Open in Phaseline: the race on ADRA2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PharmazzCenthaquine (LYFAQUIN™)
α2B-adrenergic receptor agonist (venous) and α2A-adrenergic receptor agonist (arterial); e
ADRA2B, ADRA2APhase 4Hypovolemic ShockNov 2026
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
Cooper Norcross HealthClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4Neonatal Abstinence SyndromeDec 2026
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,Brimonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4GlaucomaDec 2026
Sunnybrook Health Sciences CentreDexmedetomidine Hydrochloride
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4DeliriumDec 2026
John O'TooleClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4Lumbar Spinal StenosisFeb 2027
Peking University First HospitalIntranasal dexmedetomidine-esketamine
Combination of alpha-2 adrenergic agonist and NMDA receptor antagonist
ADRA2A, NMDAR, ADRA2B, ADRA2C, GRIN1Phase 4Adenotonsillectomy; General AnesthesiaFeb 2027
Region SkaneClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4Osteo Arthritis of the KneeMar 2027
University of Sao Paulo General Hospitalclonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4Cocaine Use DisorderJul 2027
University Hospital Dubravaclonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4Inguinal HerniaSep 2027
Damanhour Teaching HospitalDexmedetomidine Hydrochloride
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4AnalgesiaDec 2027
Columbia UniversityClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4Cesarean DeliveryMay 2028
Children's Hospital Medical Center, CincinnatiGuanfacine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 4Attention-Deficit/Hyperactivity Disorder (ADHD)Feb 2030
Prairie Eye CenterSimbrinza
Alpha-2 adrenergic receptor agonist and carbonic anhydrase inhibitor
ADRA2A, ADRA2BPhase 4Open Angle Glaucoma–
Alcon ResearchApraclonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 3Ocular HyperemiaJan 2027
Wake Forest University Health SciencesClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 3PTSDMar 2027
Stanford UniversityTizanidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 3Chronic PainJan 2028
Acer TherapeuticsCeliprolol (ACER-002)
Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist
ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1Phase 3Vascular Ehlers-Danlos SyndromeMar 2029
University of Maryland, BaltimoreLofexidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Opioid WithdrawalNov 2026
Washington State UniversityMirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2Stimulant Use DisorderDec 2026
University of Triestemirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2RETT Syndrome With Proven MECP2 MutationDec 2026
Teikoku Pharma USADexmedetomidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2AgitationMay 2027
M.D. Anderson Cancer CenterMirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2Advanced CancerDec 2027
Copenhagen University Hospital, RigshospitaletClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Emergence DeliriumJan 2028
Hartford HospitalTizanidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Post OperativeJul 2028
Stanford UniversityGuanfacine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2DepressionOct 2028
Indiana UniversityGuanfacine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Alcohol Use DisorderAug 2029
University of California, IrvineMirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2Glioma of BrainDec 2030
Universidade Federal do Rio de JaneiroClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Hernia, Umbilical–
Guangzhou Novaken PharmDexmedetomidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Preoperative Sedation; Emergence Delirium; Laceration of Skin; Vaginal Delivery …–
Yale UniversityGuanfacine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Alcohol Use–
OrygenGuanfacine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Cannabis Use Disorder–
BioCorRx Pharmaceuticals IncLofexidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Opioid Withdrawal (Disorder)–
Tarian PharmaTAR-0520 Gel
Brimonidine tartrate - selective alpha-2 adrenergic receptor agonist
ADRA2A, ADRA2B, ADRA2CPhase 2EGFR Inhibitor-associated Rash–
BioXcel TherapeuticsDexmedetomidine (BXCL501)
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 1SchizophreniaJul 2027
University of Kansas Medical CenterClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 1Blood PressureAug 2027
Satish R. RajClonidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 1TachycardiaDec 2029
Research Institute of Ophthalmology, EgyptDexmedetomidine Hydrochloride
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 1Patients Undergoing External Dacrocystorhinostomy Operations–
Rutgers, The State University of New JerseyGuanfacine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 1Mindfulness–

Conditions

Delirium (4) Emergence Delirium (3) Breast Cancer (3) Anesthesia (3) Alcohol Use Disorder (3) Laceration of Skin (2) Postoperative Pain (2) General Anesthesia (2) Cesarean Delivery (2) Insomnia (2) Agitation (2) Mental Disorder (2)

Modalities

small molecule (35), protein or peptide (2), mixed (1)

Companies

Stanford University (2) University of Kansas Medical Center (1) Guangzhou Novaken Pharm (1) Copenhagen University Hospital, Rigshospitalet (1) Universidade Federal do Rio de Janeiro (1) Wake Forest University Health Sciences (1) M.D. Anderson Cancer Center (1) Indiana University (1) Research Institute of Ophthalmology, Egypt (1) University of Maryland, Baltimore (1) Pharmazz (1) University Hospital Dubrava (1) Rutgers, The State University of New Jersey (1) BioXcel Therapeutics (1) Washington State University (1) Teikoku Pharma USA (1) Sunnybrook Health Sciences Centre (1) Hartford Hospital (1) University of California, Irvine (1) Tarian Pharma (1)

Related targets

ADRA2A (39) ADRA2C (37) HTR2A (5) HTR2C (5) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) Ion channels (1) CACNB4 (1) CACNB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.